158 related articles for article (PubMed ID: 17199883)
1. Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment.
Mellwig KP; van Buuren F; Schmidt HK; Wielepp P; Burchert W; Horstkotte D
Ther Apher Dial; 2006 Dec; 10(6):510-7. PubMed ID: 17199883
[TBL] [Abstract][Full Text] [Related]
2. [Myocardial perfusion under H.E.L.P. -apheresis. Objectification by PET].
Mellwig KP; Baller D; Schmidt HK; V Buuren F; Wielepp JP; Burchert W; Horstkotte D
Z Kardiol; 2003; 92(Suppl 3):III30-7. PubMed ID: 14663599
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses)].
Blessing F; Jaeger BR; Oberhoffer M; Reichart B; Seidel D
Z Kardiol; 2003; 92(Suppl 3):III42-7. PubMed ID: 14663601
[TBL] [Abstract][Full Text] [Related]
4. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
Seidel D
Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
[TBL] [Abstract][Full Text] [Related]
5. [Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].
Horstkotte D; Mellwig KP
Z Kardiol; 2003; 92(Suppl 3):III1-5. PubMed ID: 14663596
[TBL] [Abstract][Full Text] [Related]
6. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia.
Igarashi K; Tsuji M; Nishimura M; Horimoto M
J Clin Apher; 2004; 19(1):11-6. PubMed ID: 15095396
[TBL] [Abstract][Full Text] [Related]
7. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
Aengevaeren WR; Kroon AA; Stalenhoef AF; Uijen GJ; van der Werf T
J Am Coll Cardiol; 1996 Dec; 28(7):1696-704. PubMed ID: 8962554
[TBL] [Abstract][Full Text] [Related]
8. [Clinical long-term results of H.E.L.P.-apheresis].
Schuff-Werner P
Z Kardiol; 2003; 92(Suppl 3):III28-9. PubMed ID: 14663598
[TBL] [Abstract][Full Text] [Related]
9. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
Thiery J; Seidel D
Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
[TBL] [Abstract][Full Text] [Related]
10. Improvement of coronary vasodilatation capacity through single LDL apheresis.
Mellwig KP; Baller D; Gleichmann U; Moll D; Betker S; Weise R; Notohamiprodjo G
Atherosclerosis; 1998 Jul; 139(1):173-8. PubMed ID: 9699905
[TBL] [Abstract][Full Text] [Related]
11. [H.E.L.P. apheresis and oxidative stress].
Pulawski E; Mellwig KP; Horstkotte D
Z Kardiol; 2003; 92(Suppl 3):III38-41. PubMed ID: 14663600
[TBL] [Abstract][Full Text] [Related]
12. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia.
Park JW; Merz M; Braun P
Atherosclerosis; 1998 Aug; 139(2):401-9. PubMed ID: 9712348
[TBL] [Abstract][Full Text] [Related]
13. Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography.
Jaeger BR; Bengel FM; Odaka K; Uberfuhr P; Labarrere CA; Bengsch S; Engelschalk C; Kreuzer E; Reichart B; Schwaiger M; Seidel D
J Heart Lung Transplant; 2005 Dec; 24(12):2022-30. PubMed ID: 16364844
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia.
Wu MD; Moccetti F; Brown E; Davidson BP; Atkinson T; Belcik JT; Giraud G; Duell PB; Fazio S; Tavori H; Tsimikas S; Lindner JR
JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1430-1440. PubMed ID: 29909101
[TBL] [Abstract][Full Text] [Related]
15. Lipid apheresis: oxidative stress, rheology, and vasodilatation.
Mellwig KP; Pulawski E; Horstkotte D; van Buuren F
Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):45-9. PubMed ID: 22528131
[TBL] [Abstract][Full Text] [Related]
16. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis].
Thiery J; Seidel D
Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888
[TBL] [Abstract][Full Text] [Related]
17. Shear stress-dependent platelet function after LDL cholesterol apheresis.
Spieker LE; Ruschitzka F; Badimon JJ; Noll G; Corti R
Thromb Res; 2004; 113(6):395-8. PubMed ID: 15226094
[TBL] [Abstract][Full Text] [Related]
18. [Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia].
Baller D; Gleichmann U; Notohamiprodjo G; Weise R; Holzinger J; Montanus H; Betker S; Lehmann J
Z Kardiol; 1998; 87 Suppl 2():136-44. PubMed ID: 9827472
[TBL] [Abstract][Full Text] [Related]
19. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
Kroon AA; van Asten WN; Stalenhoef AF
Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
[TBL] [Abstract][Full Text] [Related]
20. Long-term prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia.
Jaeger BR; Tsobanelis T; Bengel F; Schwaiger M; Seidel D
J Pediatr; 2002 Jul; 141(1):125-8. PubMed ID: 12091863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
